Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1643
This examiner grants 54% of resolved cases
Bradley Duffy is an examiner in Art Unit 1643 of Tech Center 1600. With 752 resolved cases, the examiner has an allowance rate of 54.5%. This rate indicates a moderate probability of success for patent applicants. The median days to allowance is 1364, providing a timeline for successful prosecution.
The interview lift is 45.8%, suggesting that interviews are an effective way to increase the chances of allowance relative to the 54.5% baseline. Practitioners should strongly consider an interview to take advantage of the 45.8% lift. The 752 resolved cases offer a robust data set.
In Tech Center 1600, the 54.5% allowance rate and 1364-day median timeline offer a strategic path for applicants in Art Unit 1643. Utilizing the 45.8% interview lift can significantly improve outcomes. These data points are essential for informed decision-making.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17575762 | CHIMERIC ANTIGEN RECEPTOR COMPRISING INTERLEUKIN-15 INTRACELLULAR DOMAIN AND USES THEREOF | Final Rejection | University of Florida Research Foundation, Incorporated |
| 19637868 | Subcutaneous Formulations Of Anti-CD38 Antibodies And Their Uses | Non-Final OA | Janssen Biotech, Inc. |
| 19637933 | Subcutaneous Formulations Of Anti-CD38 Antibodies And Their Uses | Non-Final OA | Janssen Biotech, Inc. |
| 19277274 | COMPOSITIONS AND METHODS RELATED TO POTENT CYTOTOXIC M-CENK CELLS FROM CD3/CD14-DEPLETED APHERESIS PRODUCTS | Final Rejection | ImmunityBio, Inc. |
| 18691685 | COMPOSITIONS OF CHIMERIC ANTIGEN RECEPTOR (CAR) SIGNALING MOLECULES AND USES THEREOF | Non-Final OA | The Board of Trustees of the Leland Stanford Junior University |
| 18491633 | METHODS AND COMPOSITIONS FOR ADOPTIVE CELL THERAPY | Final Rejection | Juno Therapeutics, Inc. |
| 18169293 | AMHR2-ED CANCER VACCINE FORMULATIONS | Final Rejection | The Cleveland Clinic Foundation |
| 17819745 | PD-L1 ANTIBODIES BINDING CANINE PD-L1 | Non-Final OA | Intervet Inc. |
| 17775063 | ENGINEERING CHARGE PAIR MUTATIONS FOR PAIRING OF HETERO-IgG MOLECULES | Final Rejection | AMGEN INC. |
| 18164304 | TREATMENT OF ACUTE LYMPHOBLASTIC LEUKEMIA | Non-Final OA | AMGEN RESEARCH (MUNICH) GMBH |
| 18066972 | CROSS-SPECIES-SPECIFIC BINDING DOMAIN | Non-Final OA | Amgen Research (Munich) GmbH |
| 18703318 | ANTI-TSHR MULTI-SPECIFIC ANTIBODIES AND USES THEREOF | Non-Final OA | Sloan-Kettering Institute for Cancer Research |
| 18043527 | METHODS AND COMPOSITIONS FOR TARGETING CYTOSOLIC DSDNA SIGNALING IN CHROMOSOMALLY UNSTABLE CANCERS | Non-Final OA | MEMORIAL SLOAN KETTERING CANCER CENTER |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy